Coinfection

Coverage of the 2014 Conference on Retroviruses and Opportunistic Infections

HIVandHepatitis.com coverage of the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014), March 3-6, 2014, in Boston.

Conference highlights include new treatments for hepatitis C, HIV experimental therapies and treatment strategies, HIV cure research, HIV-related conditions, treatment as prevention and PrEP, and HIV/HCV coinfection.

Full listing by topic

Selected presentations and slide webcasts 

3/9/14

alt

Coverage of the 2014 Conference on Retroviruses and Opportunistic Infections

HIVandHepatitis.com coverage of the 21st Conference on Retroviruses and Opportunistic infections (CROI 2014), March 3-6, 2014, in Boston.

Conference highlights include new treatments for hepatitis C, HIV experimental therapies and treatment strategies, HIV cure research, HIV-related conditions, treatment as prevention and PrEP, and HIV/HCV coinfection.

Full HIVandHepatitis.com coverage by topic

Selected presentations and slide webcasts 

3/9/14

alt

AASLD Liver Meeting Starts this Weekend in Washington, DC

The American Association for the Study of Liver Diseases (AASLD) annual Liver Meeting gets underway this Friday, running November 1-5 at the Walter E. Washington Convention Center in Washington, DC. The highlight of this year's meeting will be numerous presentations on next-generation direct-acting antivirals (DAAs) for hepatitis C, now in late stages of development, both as interferon add-ons and in interferon-free regimens.

alt

Read more:

CROI 2014: Retrovirus Conference Now Underway in Boston

The 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) kicked off in Boston this week with a program for young investigators, a press conference on new hepatitis C treatments, and opening lectures on HIV immune response and cross-species transmission and an update on the epidemic in West Africa.

HIVandHepatitis.com will be on site all week bringing you the latest news.alt

Read more:

Coverage of the 2013 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013) in Boston, November 1-5, 2013.

Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, HIV/HBV and HIV/HCV coinfection, and prevention and treatment of hepatocellular carcioma.

Full listing by topic

10/30/13

alt

CROI 2014: The Role of Interferon in HIV Response [VIDEO]

Although interferon is on its way out as a standard of care for hepatitis C, researchers are learning more about its role in HIV, conference vice chair Julie Overbaugh said at a media briefing on the opening day of the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston.

alt

Read more:

ICAAC 2013: Liver Cancer Often Diagnosed Late with Poor Survival in People with HIV

Hepatocellular carcinoma (HCC) is frequently diagnosed at an advanced stage in HIV positive people with hepatitis B or C coinfection, contributing to a high mortality rate that has changed little in recent years, according to a report at the recent 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) in Denver.

alt

Read more:

CROI 2014: Retrovirus Conference Starts Monday in Boston

The 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) will take place next week, March 3-6, at the Hynes Convention Center in Boston. HIVandHepatitis.com will be on site all week to bring you the latest news coverage about HIV, hepatitis C, and related topics.

alt

Read more:

Tenofovir Is Highly Effective for HIV/HBV Coinfection, Meta-analysis Shows

Tenofovir, which has potent activity against both HIV and hepatitis B virus (HBV), is the most effective hepatitis B treatment for HIV/HBV coinfected people, according to a 23-study meta-analysis described in the July 10, 2013, issue of the open-access journal PLoS One. Combining it with emtricitabine did not improve hepatitis B response.

alt

Read more: